share_log

IDEAYA Biosciences (NASDAQ:IDYA) Given New $32.00 Price Target at Guggenheim

Financial News Live ·  Sep 17, 2022 03:31

IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) had its price objective boosted by Guggenheim from $20.00 to $32.00 in a research note released on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also issued reports on IDYA. Stifel Nicolaus lowered IDEAYA Biosciences from a buy rating to a hold rating and decreased their target price for the company from $16.00 to $13.00 in a research report on Monday, August 15th. Roth Capital raised their target price on IDEAYA Biosciences from $42.00 to $46.00 in a research report on Tuesday, May 17th. Oppenheimer raised their target price on IDEAYA Biosciences to $22.00 in a research report on Tuesday, September 6th. Finally, Robert W. Baird decreased their target price on IDEAYA Biosciences from $26.00 to $18.00 and set an outperform rating for the company in a research report on Tuesday, August 16th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences has a consensus rating of Moderate Buy and an average target price of $27.50.

Get IDEAYA Biosciences alerts:

IDEAYA Biosciences Trading Down 5.1 %

NASDAQ IDYA opened at $11.16 on Tuesday. The firm has a market capitalization of $438.65 million, a P/E ratio of -6.53 and a beta of 1.51. The business has a fifty day simple moving average of $12.84 and a 200 day simple moving average of $12.01. IDEAYA Biosciences has a 12 month low of $8.14 and a 12 month high of $27.71.

IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). IDEAYA Biosciences had a negative net margin of 225.95% and a negative return on equity of 22.38%. As a group, sell-side analysts predict that IDEAYA Biosciences will post -2.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in IDYA. Nisa Investment Advisors LLC bought a new position in IDEAYA Biosciences in the 2nd quarter worth about $25,000. Point72 Hong Kong Ltd boosted its stake in IDEAYA Biosciences by 363.7% in the 1st quarter. Point72 Hong Kong Ltd now owns 3,376 shares of the company's stock worth $38,000 after purchasing an additional 2,648 shares during the period. Quantbot Technologies LP boosted its stake in IDEAYA Biosciences by 90.5% in the 1st quarter. Quantbot Technologies LP now owns 4,000 shares of the company's stock worth $44,000 after purchasing an additional 1,900 shares during the period. Amalgamated Bank bought a new position in IDEAYA Biosciences in the 1st quarter worth about $48,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in IDEAYA Biosciences by 12.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,416 shares of the company's stock worth $117,000 after purchasing an additional 1,171 shares during the period. Institutional investors own 93.25% of the company's stock.

IDEAYA Biosciences Company Profile

(Get Rating)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.

See Also

  • Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
  • 3 Banks Worth Considering For Q4
  • Stock Market: 3 Islands Of Strength In A Sea Of Red
  • No One Told These 3 Stocks It's a Down Week
  • MarketBeat: Week in Review 9/12 – 9/16
  • Is There a Cure for What is Ailing Teladoc Stock?

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment